推进神经药理学与神经退行性疾病治疗：弥合差距与开辟新途径。
Advancing Neuropharmacology and Neurodegenerative Disease Therapy: Bridging Gaps and Paving New Pathways.
作者信息
Leri Manuela, Vasarri Marzia
机构信息
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
出版信息
Pharmaceuticals (Basel). 2025 Apr 22;18(5):606. doi: 10.3390/ph18050606.
Abstract
The Special Issue of , titled "Multi-target drug treatments for neurodegenerative disease", highlighted recent advancements in neuropharmacology and the therapeutic landscape for neurodegenerative diseases, representing a significant stride forward in our understanding of these complex conditions [...].
摘要
《……》特刊，题为“神经退行性疾病的多靶点药物治疗”，突出了神经药理学的最新进展以及神经退行性疾病的治疗前景，代表了我们对这些复杂病症理解上的重大进步[……]
相似文献
1
Advancing Neuropharmacology and Neurodegenerative Disease Therapy: Bridging Gaps and Paving New Pathways.推进神经药理学与神经退行性疾病治疗：弥合差距与开辟新途径。
Pharmaceuticals (Basel). 2025 Apr 22;18(5):606. doi: 10.3390/ph18050606.
2
Neuropharmacology beyond reductionism - A likely prospect.超越还原论的神经药理学——一个可能的前景。
Biosystems. 2016 Mar;141:1-9. doi: 10.1016/j.biosystems.2015.11.010. Epub 2015 Dec 23.
3
Neuropharmacology of Organoselenium Compounds in Mental Disorders and Degenerative Diseases.有机硒化合物在精神障碍和退行性疾病中的神经药理学。
Curr Med Chem. 2023;30(21):2357-2395. doi: 10.2174/0929867329666220615124412.
4
National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities.美国国立卫生研究院裸盖菇素研究演讲系列：科学现状、监管和政策格局、研究差距和机遇。
Neuropharmacology. 2023 Jun 1;230:109467. doi: 10.1016/j.neuropharm.2023.109467. Epub 2023 Feb 27.
5
Resting state functional connectivity: its physiological basis and application in neuropharmacology.静息态功能连接性：其生理基础及在神经药理学中的应用
Neuropharmacology. 2014 Sep;84:79-89. doi: 10.1016/j.neuropharm.2013.08.023. Epub 2013 Sep 4.
6
Building Bridges In Neuropharmacology: New therapeutic approaches for psychiatric and neurodegenerative disorders.搭建神经药理学的桥梁：精神疾病和神经退行性疾病的新治疗方法
Br J Pharmacol. 2022 Apr;179(8):1475-1477. doi: 10.1111/bph.15711.
7
Introduction to the College on Problems of Drug Dependence special issue: contemporary advances in opioid neuropharmacology.《药物依赖问题学院专刊介绍》：阿片类神经药理学的当代进展。
Drug Alcohol Depend. 2010 May 1;108(3):153-5. doi: 10.1016/j.drugalcdep.2010.03.001. Epub 2010 Apr 7.
8
The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?神经胶质细胞对脑内递送的神经退行性疾病治疗方法的反应：这是一个关键问题吗？
Front Pharmacol. 2014 Jul 10;5:139. doi: 10.3389/fphar.2014.00139. eCollection 2014.
9
Advancing methods in big data capture, integration, classification and liberation.推进大数据捕获、集成、分类和解放的方法。
BMC Res Notes. 2023 Apr 27;16(1):64. doi: 10.1186/s13104-023-06340-z.
10
Drug discovery in neurodegenerative diseases.神经退行性疾病中的药物发现
Sci Aging Knowledge Environ. 2005 Feb 9;2005(6):pe4. doi: 10.1126/sageke.2005.6.pe4.
本文引用的文献
1
Promising Strategies to Reduce the SARS-CoV-2 Amyloid Deposition in the Brain and Prevent COVID-19-Exacerbated Dementia and Alzheimer's Disease.减少新冠病毒在大脑中的淀粉样蛋白沉积并预防新冠病毒加剧的痴呆症和阿尔茨海默病的潜在策略。
Pharmaceuticals (Basel). 2024 Jun 16;17(6):788. doi: 10.3390/ph17060788.
2
Enzymatic Metabolic Switches of Astrocyte Response to Lipotoxicity as Potential Therapeutic Targets for Nervous System Diseases.星形胶质细胞对脂毒性反应的酶促代谢开关作为神经系统疾病的潜在治疗靶点
Pharmaceuticals (Basel). 2024 May 16;17(5):648. doi: 10.3390/ph17050648.
3
Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease.钠-葡萄糖协同转运蛋白2抑制剂卡格列净与多奈哌齐联合治疗阿尔茨海默病的临床前研究
Pharmaceuticals (Basel). 2023 Nov 16;16(11):1620. doi: 10.3390/ph16111620.
4
Patient-Derived Cellular Models for Polytarget Precision Medicine in Pantothenate Kinase-Associated Neurodegeneration.泛酸激酶相关神经变性中用于多靶点精准医学的患者来源细胞模型
Pharmaceuticals (Basel). 2023 Sep 26;16(10):1359. doi: 10.3390/ph16101359.
5
Multitargeted Virtual Screening and Molecular Simulation of Natural Product-like Compounds against GSK3β, NMDA-Receptor, and BACE-1 for the Management of Alzheimer's Disease.针对糖原合成酶激酶3β、N-甲基-D-天冬氨酸受体和β-分泌酶1的天然产物类化合物的多靶点虚拟筛选及分子模拟用于阿尔茨海默病的治疗
Pharmaceuticals (Basel). 2023 Apr 20;16(4):622. doi: 10.3390/ph16040622.
Zotero 插件